Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.

The Journal of molecular diagnostics : JMD - 1 Mar 2016

Zhang Jinglan, Fedick Anastasia, Wasserman Stephanie, Zhao Geping, Edelmann Lisa, Bottinger Erwin P, Kornreich Ruth, Scott Stuart A

Abstract excerpt

The incidence of chronic kidney disease (CKD) varies by ancestry, with African Americans (AA) having a threefold to fourfold higher rate than whites. Notably, two APOL1 alleles, termed G1 [c.(1072A>G; 1200T>G)] and G2 (c.1212_1217del6), are strongly associated with higher rates of nondiabetic CKD and an increased risk for hypertensive end-stage renal disease. This has prompted the opportunity to implement APOL1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein L1
Share to Apolipoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hispanic or Latino

Share to Lipoproteins, HDL

Share to Multiplex Polymerase Chain Reaction

Share to New York City

Share to Renal Insufficiency, Chronic

Source

Open in PubMed Open full text

Identifiers

PMID: 26773863
DOI: 10.1016/j.jmoldx.2015.11.003
PMCID: PMC4816711

Genes

APOL1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.PMID 26773863Read ↗

Population-based risk assessment of APOL1 on renal disease.Semantic proximity Read ↗

A multiplex allele-specific polymerase chain reaction assay for rapid and affordable detection of APOL1 risk variants.Semantic proximity Read ↗

Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry.Semantic proximity Read ↗

Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.Semantic proximity Read ↗

APOL1 variants associate with increased risk of CKD among African Americans.Semantic proximity Read ↗

Prevalence of Mendelian kidney disease among patients with high-risk<i>APOL1</i>genotypes undergoing commercial genetic testing in the United StatesSemantic proximity Read ↗

Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes.Semantic proximity Read ↗

APOL1 Kidney Risk Variants and Proteomics.Semantic proximity Read ↗

Association of APOL1 Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran ProgramSemantic proximity Read ↗

Multi-ethnic polygenic risk modifies the association between <i>APOL1</i> high risk genotypes and chronic kidney diseaseSemantic proximity Read ↗

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.Semantic proximity Read ↗

"Biomarking" the transition from genetic risk to kidney disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.